ArticleCureus2025
Cancer-Associated Venous Thromboembolic Disease: Anatomoclinical Aspects and Risk Factors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cancer represents an independent risk factor for venous thromboembolic disease (VTE). The main objective of this study is to analyze the cancer profile as well as the related VTE risk factors. Materials and methods A retrospective, descriptive, and analytical study was conducted in the Gabes University Hospital from January 2017 to May 2021. The data study collection focused on patients hospitalized with VTE-associated cancer. Input data and statistical analysis were performed using IBM SPSS Statistics for Windows, Version 26 (Released 2019; IBM Corp., Armonk, New York, United States). Results The study involved 135 patients. The average age of the patients was 59.21 years, ranging from 17 to 94 years, and the sex ratio of 1.81. Lung, pancreatic, and bladder cancers significantly increased the risk of VTE by 1.48 (95% CI [1.19-1.85]), 2.60 (95% CI [1.31-5.3]), and 2.61 (95% CI [1.26-5.4]), respectively. Among the patients with metastatic cancer, the risk of developing VTE was 1.55 times higher than patients without metastatic cancer (95% CI [1.1-2.1]). Small cell, squamous cell, and urothelial carcinoma significantly increased (p<0.001) the risk of VTE occurrence by 2.79 (95% CI [1.69-4.6]), 2.41 (95% CI [1.38-4.13]), and 3.03 (95% CI [1.33-6.8]), respectively. Conclusion Among the patients with metastatic cancer, the risk of developing VTE was higher than patients without metastatic cancer. In addition, small cell, squamous cell, and urothelial carcinoma significantly increased the risk of VTE. Problems and knowledge of the VTE risk factors among cancer patients allow for cancer management improvement as well as avoiding further thromboembolic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.